Pharmanutra S.P.A.

9 patents currently held · Updated Nov 15, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Jul 2033

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due May 14, 2027
The maintenance fee for Solid compositions based on minerals and orally disintegrating formulations containing the same (US 11,813,290) comes due May 14, 2027. Unpaid by Nov 15, 2027, it lapses early.
1 fee due Sep 24, 2027
The maintenance fee for Cetylated Fatty Acids, System for the Preparation Thereof and Use Thereof (US 10,597,608) comes due Sep 24, 2027. Unpaid by Mar 24, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 9 of 9

Patent	Title	Status	Expires	Confidence
US 10,183,077	Solid composition comprising iron for use in iron deficient conditions In force Term ends Jul 30, 2033 · From the USPTO record	In force	Term ends Jul 30, 2033	From the USPTO record
US 10,765,752	Solid composition comprising iron for use in iron deficient conditions In force Term ends Jul 30, 2033 · From the USPTO record	In force	Term ends Jul 30, 2033	From the USPTO record
US 11,813,290	Solid compositions based on minerals and orally disintegrating formulations containing the same In force Ends no later than Sep 9, 2034 · From the USPTO record	In force	Ends no later than Sep 9, 2034	From the USPTO record
US 10,597,608	Cetylated Fatty Acids, System for the Preparation Thereof and Use Thereof In force Term ends Aug 9, 2036 · High confidence	In force	Term ends Aug 9, 2036	High confidence
US 11,186,536	Cetylated Fatty Acids, System for the Preparation Thereof and Use Thereof In force Term ends Aug 9, 2036 · High confidence	In force	Term ends Aug 9, 2036	High confidence
US 12,246,036	Composition for use in the prevention and in the treatment of iron deficiency In force Term ends Jul 27, 2038 · From the USPTO record	In force	Term ends Jul 27, 2038	From the USPTO record
US 12,383,525	Compositions Comprising Cetylated Fatty Acids and Use Thereof for the Treatment of Arthritis and Joint Inflammatory Conditions In force Term ends May 11, 2042 · High confidence	In force	Term ends May 11, 2042	High confidence
US 12,691,091	Compositions Comprising Cetylated Fatty Acids for Use in the Treatment of Gastric Mucosa, Diabetes and High Blood Glucose Levels In force Term ends May 11, 2042 · High confidence	In force	Term ends May 11, 2042	High confidence
US 12,297,406	Method for Preparing a Composition Comprising Cetylated Fatty Acids In force Term ends May 12, 2042 · High confidence	In force	Term ends May 12, 2042	High confidence

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 pending · 2 no status recorded

List them